ArticleCardiovascular therapeutics2026
Anthracycline Cardiotoxicity: A Real-World Study Based on FDA Adverse Event Reporting System Database.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anthracycline Cardiotoxicity: A Real-World Study Based on FDA Adverse Event Reporting System Database.Cardiovascular therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveBased on the FDA Adverse Event Reporting System (FAERS) database, data mining of adverse event (AE) signals related to anthracyclines was conducted to explore their potential medication risks, especially cardiotoxicity, in order to promote the rational and safe use of these drugs in clinical practice.
methodsAE data for anthracyclines (represented by aclarubicin, daunorubicin, doxorubicin, and epirubicin) commonly used to treat hematologic malignancies and solid tumors were retrieved from the FAERS database from January 1, 2004, to June 30, 2025. Disproportionation analysis was primarily used to mine signals of AEs related to anthracyclines.
resultsA total of 324 AE reports related to aclarubicin, 298 related to daunorubicin, 822 related to doxorubicin, and 334 related to epirubicin were extracted from the FAERS database. Based on risk signal detection using the Bayesian confidence propagation neural network (BCPNN) for cardiac AEs: For aclarubicin, left ventricular dysfunction exhibited the strongest risk signal among AEs with positive risk signals, whereas cardiac failure had the largest number of reports. For daunorubicin, supraventricular arrhythmia represented the strongest risk signal among AEs with positive risk signals, and tachycardia had the highest reporting count. For doxorubicin, acute cardiomyopathy showed the strongest risk signal among AEs with positive risk signals, whereas cardiac failure possessed the greatest number of reports. For epirubicin, heart failure with midrange ejection fraction yielded the strongest risk signal among AEs with positive risk signals, and cardiac failure had the largest number of reports.
conclusionThis study provides a more comprehensive insight into the monitoring, supervision, and management of adverse reactions related to anthracyclines. Clinicians should further focus on the impact of various AEs related to anthracyclines and their corresponding signal strengths, especially the cardiotoxicity of anthracyclines, which is of great value for improving the clinical safety of anthracyclines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.